Citigroup
BHVN

Citigroup’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Citigroup’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,000
Closed -$1.07M – 6953
2022
Q1 		$1.07M Buy
+9,000
New +$1.12M ﹤0.01% 2901
2020
Q1 		– Sell
-30,000
Closed -$1.63M – 8000
2019
Q4 		$1.63M Buy
+30,000
New +$1.49M ﹤0.01% 3229

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Citigroup's BHVN Position: Q4 2022 in Review

Citigroup sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 361,076 shares — an estimated $54.6M sold.

Citigroup first reported a position in BHVN in Q2 2017 and held it in 21 quarters. The position peaked at $54.6M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Citigroup reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 361,076 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $54.6M.
  • Citigroup first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 21 quarters.
  • Citigroup's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $54.6M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.